Explosive Growth Launches Kraspharma Into REMEDIUM TOP-5

Rafarma Pharmaceuticals, Inc. (OTC: RAFA) reports that PJSC Kraspharma at the end of 2020 entered the TOP-5 of the most dynamic and largest pharmaceutical companies in Russia for 2020, showing incredible growth rates with a net profit increase of 220.9% compared to 2019. Specifically, Kraspharma went from $5,563,056 (USD) at the end of 2019 to $17,853,905 at the end of 2020. The growth was featured in the ratings by the authoritative Russian industry publication "Remedium", published in Q3 of 2021.

Remedium's ratings are calculated based on the annual financial statements of 90 companies representing the largest pharmaceutical companies in the country. Remedium’s ratings only include profitable businesses. According to these standards, PJSC Kraspharma entered the top five largest companies in terms of gross profit growth dynamics, outpacing the long-term leaders of this rating by ten times. The company also entered the TOP-30 of the largest pharmaceutical companies in terms of gross profit, retaining its position since 2019.


Also, according to the monthly monitoring of the Russian pharmaceutical market compiled by DSM Group, for the first nine months of 2020 PJSC Kraspharma entered the TOP-5 rating of manufacturers of antibacterial agents for systemic use. During the reporting period, PJSC Kraspharma increased the volume of sold antibiotics by more than 40%. For more details see Cyberleninka, Kommersant or Elibrary articles.


Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

SOURCE: Rafarma Pharmaceuticals, Inc.